Opioidsubstitutionsbehandlung und Cannabiskonsum

Zusammenfassung

Ziel der Studie Mehr als 30 % der Patienten in Opioidsubstitutionsbehandlung konsumieren zusätzlich Cannabis. In dem Artikel werden die Auswirkungen des Konsums von Cannabis im Rahmen einer Opioidsubstitutionsbehandlung dargestellt.

Methodik Narrative Literaturrecherche (Medline, PubMed)

Ergebnisse Der Konsum von Cannabis im Rahmen einer Opioidsubstitutionsbehandlung kann negative Folgen nach sich ziehen.

Schlussfolgerung Der Konsum von Cannabis im Rahmen einer Substitutionsbehandlung sollte mit dem Patienten erörtert werden. Cannabiskonsum stellt grundsätzlich keinen Grund für den Abbruch einer Substitutionsbehandlung dar.

Abstract

Objectives More than 30 % of patients participating in an opioid maintenance program consume cannabis. This article describes the effects of additional cannabis use during an opioid maintenance treatment program.

Methods Narrative literature research using online publication databases (MedLine, PubMed)

Results The additional use of cannabis during an opioid maintenance treatment program may have negative side effects.

Conclusion Cannabis use should be discussed with the patient. It is in principle not a reason for discontinuing an opioid maintenance treatment program.

Schlüsselwörter

Opioidsubstitutionsbehandlung - Cannabiskonsum - unerwünschte Wirkungen

Key words

Opioid maintenance program - side effects - cannabis use

• Literatur

• 1 Kunstmann W, Hessenauer F. Substitution Opiatabhängiger: Versorgung wird schwieriger. Dtsch Arztebl 2009; 106: A-1508
• 2 Bundesamt für Arzneimittel, Bericht zum Substitutionsregister, Januar 2016
• 3 Verordnung über das Verschreiben, die Abgabe und den Nachweis über das Verschreiben, die Abgabe und den Nachweis des Verbleibs von Betäubungsmitteln (Betäubungsmittel-Verschreibungsverordnung – BtMVV). Ausfertigungsdatum 20. 01.1998,zuletzt geändert durch Art. 2 V vom 02. 07.2018I 1078. Bundesgesetzblatt; I S. 74, 80 geändert Bundesgesetzblatt I S. 1078
• 4 Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opiatabhängiger, vom Vorstand der Bundesärztekammer verabschiedet 27. / 28.04.2017, mit der Veröffentlichung im Bundesanzeiger 02.10.2017 in Kraft getreten
• 5 Soyka M, Strehle J, Rehm J. et al. Six-Year outcome of opioid maintenance treatment in heroin-dependent patients: Results from a naturalistic study in a nationally representative study. Eur Addict Res 2017; 23: 97-105
• 6 Gutwinski S, Bald LK, Heinz A. et al. Substitutmitgabe bei Opiatabhängigkeit. Dtsch Arztebl Int 2013; 110: 405-412
• 7 Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; 168: 657-690
• 8 Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-348
• 9 Tomas-Roig J, Piscitelli F, Gil V. et al. Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice. Behav Brain Res 2016; 303: 34-43
• 10 Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol. 2015 doi:10.3389/fphar.2015.00006
• 11 Scavone JL, Sterling RC, Van Brockstaele EJ. Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal. Neuroscience 2013; 248: 637-654
• 12 Kathmann M, Flau K, Redmer A. et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 354-361
• 13 Havemann-Reinecke U. Zur Legalisierungsdebatte von Cannabis zum Freizeitkonsum in der Medizin aus biologischer, pharmakologischer und psychiatrischer Sicht. Blutalkohol 2018; 55 (Supp I): 19-29
• 14 Brunen S, Vincent PD, Baumann P. et al. Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: Literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 2011; 33: 561-566
• 15 Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-122
• 16 Hoch E, Bonnet U, Thomasius R. et al. Risks associated with the non-medical use of cannabis. Dtsch Arztebl Int 2015; 112 (16) : 271-278
• 17 Wiesbeck GA, Schuckit MA, Kalmijn JA. et al. An evaluation of her history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469-1478
• 18 Bolla KI, Lesage SR, Gamaldo CE. et al. Sleep disturbance in heavy marijuana users. Sleep 2008; 31: 901-908
• 19 Bonnet U, Preuss UW. The cannabis withdrawal syndrome: Current insights. Subst Abuse Rehabil 2017; 8: 9-37 doi:10.2147/SAR.S109576. eCollection 2017.
• 20 Soyka M, Preuss U, Hoch E. Cannabis-induced disorders. Nervenarzt 2017; 88 (03) : 311-325
• 21 Seifert J, Schlimme J, Wedegärtner F. et al. Cannabis und Schizophrenie. Sucht 2002; 48: 336-345
• 22 Zammit S, Allerbeck P, Andreasson S. et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 2002; 325: 1-5
• 23 Lerner AG, Goodman C, Rudinski D. et al. Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: A case series study. Isr J Psychiatry Relat Sci 2011; 48: 25-29
• 24 Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158: 2033-2037
• 25 Volkow ND, Swanson JM, Evins AE. et al. Effects of cannabis use on human behavior, including cognition, motivation and psychosis: A review. JAMA Psychiatry 2016; 73: 292-297
• 26 Solowji N, Roffman RA, Barbor T. et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131
• 27 Pope HG jr. Cannabis, cognition, and residual confounding. JAMA 2002; 287: 1172-1174
• 28 Wittchen HU, Fröhlich C, Behrendt S. et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: A 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007; 88: 60-70
• 29 Perkonigg A, Lieb R, Höfler M. et al. Patterns of cannabis use, abuse and dependence over time: Incidence, progression and stability in a sample of 1228 adolescents. Addiction 1999; 94: 1663-1678
• 30 Hölscher F, Bonnet U, Scherbaum N. Use of an outpatient treatment center for cannabis abuse. Nervenarzt 2008; 79: 571-576
• 31 Tossmann HP, Gantner A. Differentielle Aspekte der Haschischabhängigkeit. Sucht 1993; 4: 276-281
• 32 Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: Subtype differences in comorbidity, educational and clinical history. J Nerv Ment Disord 2002; 190: 147-157
• 33 Van Os J, Bak M, Hanssen M. et al. Cannabis use and psychosis: Longitudinal population based study. Am J Epidemiol 2002; 156: 319-327
• 34 Kawohl W, Rössler W. Cannabis and Schizophrenia: New findings in an old debate. Neuropsychiatr 2008; 22: 223-229
• 35 Arenault L, Cannon M, Poulton R. et al. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325: 1212-1213
• 36 Carney R, Cotter J, Firth J. et al Cannabis use and symptom serverity in individuals at ultra risk for psychosis: A meta-analysis. Acta Psychiatr Scand 2017; 136: 5-15
• 37 Casier I, Vanduynhoven P, Haine S. et al. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol 2014; 69: 131-136
• 38 Desai R, Patel U, Sharma S. et al. Recreational Marijuana use and acute myocardial infarction: Insight from nationwide inpatient sample in the United States. Cureus 2017; 9 (11) : e1816
• 39 Galvan G, Guerrero-Martelo M, Vasquez De la Hoz F. Cannabis: A cognitive illusion. Rev Colomb Psiquiatr 2017; 46 (02) : 95-102
• 40 Hannemann TV, Kraus L, Piontek D. Consumption patterns of nightlife attendees in Munich: A latent-class analysis. Subst Use Misuse 2017; 52 (11) : 1511-1521
• 41 Bell J, Mattick R, Hay A. et al. Methadone maintenance and drug related crime. J Subst Abuse 1997; 9: 15-25
• 42 Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: A review. Addiction 2000; 95 (11) : 1621-1630
• 43 Alon MH, Saint-Fleur MO. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respir Med Case Rep 2017; 29 (22) : 137-141
• 44 Moore TH, Zammit S, Lingford-Hughes A. et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370 (9584): 319-328
• 45 McLoughlin BC, Pushpa-Rajah JA, Gillies D. et al. Cannabis and schizophrenia. Cochrane Database Syst Rev 2014; 14 (10) : CD004837
• 46 Fareed A, Eilender P, Ketchen B. et al. Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med 2014; 8: 345-350
• 47 Wasserman DA, Weinstein MG, Havassy BE. et al. Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 1998; 52: 183-192
• 48 Bagra I, Krishnan V, Rao R. et al. Does cannabis use influence opioid outcomes and qualtity of life among buprenorphine maintained patients? A cross-sectional, comparative study. J Addict Med 2018; 12 (04) : 315-320
• 49 Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003; 98: 269-279
• 50 Roux P, Carrieri PM, Cohen J. et al. Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: The need for a more comprehensive approach. Harm Reduct J 2011; 8: 31
• 51 Newville H, Berg KM, Gonzalez JS. The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance. Int J Behav Med 2015; 22: 214-222
• 52 Singh A, Saluja S, Kumar A. et al. Cardiovascular complications of marijuana and related substances: A Review. Cardiol Ther 2018; 7 (01) : 45-59
• 53 Kao DP, Haigney MC, Mehler PS. et al. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction 2015; 110 (09) : 1468-1475
• 54 Rezkalla S, Kloner RA. Cardiovascular effects of marijuana. Trends Cardiovasc Med 2018; pii: S1050-1738(18)30141-5 doi:10.1016/j.tcm.2018.11.004
• 55 Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis 2017; 9 (07) : 2079-2092
• 56 Baharudin A, Mislan N, Ibrahim N. et al. Depression in male patients on methadone maintenance therapy. Asia Pac Psychiatry 2013; 5 (Suppl 1): 67-73
• 57 Villagonzalo KA, Dodd S, Ng F. et al. The relationship between substance use and posttraumatic stress disorder in an methadone maintenance treatment program. Compr Psychiatry 2011; 52: 562-566
• 58 Tull MT, McDermott MJ, Gratz KL. Marijuana dependence moderates the effect of postraumatic stress disorder on trauma cue reactivity ins substance dependent patients. Drug Alcohol Depend 2016; 159: 219-226
• 59 Schäfer I, Langeland W, Hissbach J. et al. Childhood trauma and dissociation in patients with alcohol dependence, drug dependence, or both – A multicenter study. Drug Alcohol Depend 2010; 109: 84-89